Nurix Therapeutics (NRIX) Free Cash Flow (2019 - 2026)

Nurix Therapeutics (NRIX) has reported Free Cash Flow for 8 consecutive years, with -$97.9 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Free Cash Flow fell 61.05% year-over-year to -$97.9 million; the TTM figure through May 2026 stood at -$296.8 million (down 37.42% YoY), while the FY2025 annual figure was -$250.6 million, down 43.86% from the prior year.
• Free Cash Flow declined to -$97.9 million in Q2 2026 per NRIX's latest filing, from -$73.6 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $31.9 million in Q4 2023 and bottomed at -$97.9 million in Q2 2026.
• Historically, Free Cash Flow has averaged -$47.2 million across 5 years, with a median of -$46.8 million in 2022.
• Annual changes were most pronounced in 2022 — Free Cash Flow slumped 739.42% — and 2023, when it soared 178.66%.
• Nurix Therapeutics' Free Cash Flow stood at -$40.5 million in 2022, then jumped by 178.66% to $31.9 million in 2023, then sank by 235.62% to -$43.2 million in 2024, then slumped by 54.76% to -$66.9 million in 2025, then slumped by 46.28% to -$97.9 million in 2026.
• Business Quant data shows NRIX's Free Cash Flow at -$97.9 million in Q2 2026, -$73.6 million in Q1 2026, and -$66.9 million in Q4 2025.